Literature DB >> 34156974

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.

Seth J Zost1,2, Jinhui Dong1, Iuliia M Gilchuk1, Pavlo Gilchuk1, Natalie J Thornburg1, Sandhya Bangaru2, Nurgun Kose1, Jessica A Finn1,2, Robin Bombardi1, Cinque Soto1,3, Elaine C Chen1,2, Rachel S Nargi1, Rachel E Sutton1, Ryan P Irving1, Naveenchandra Suryadevara1, Jonna B Westover4, Robert H Carnahan1,3, Hannah L Turner5, Sheng Li6, Andrew B Ward5, James E Crowe1,2,3.   

Abstract

Broadly reactive antibodies targeting the influenza A virus hemagglutinin (HA) head domain are thought to be rare and to require extensive somatic mutations or unusual structural features to achieve breadth against divergent HA subtypes. Here we describe common genetic and structural features of protective human antibodies from several individuals recognizing the trimer interface (TI) of the influenza A HA head, a recently identified site of vulnerability. We examined the sequence of TI-reactive antibodies, determined crystal structures for TI antibody-antigen complexes, and analyzed the contact residues of the antibodies on HA to discover common genetic and structural features of TI antibodies. Our data reveal that many TI antibodies are encoded by a light chain variable gene segment incorporating a shared somatic mutation. In addition, these antibodies have a shared acidic residue in the heavy chain despite originating from diverse heavy chain variable gene segments. These studies show that the TI region of influenza A HA is a major antigenic site with conserved structural features that are recognized by a common human B cell public clonotype. The canonical nature of this antibody-antigen interaction suggests that the TI epitope might serve as an important target for structure-based vaccine design.

Entities:  

Keywords:  Immunoglobulins; Immunology; Influenza

Year:  2021        PMID: 34156974      PMCID: PMC8321569          DOI: 10.1172/JCI146791

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus.

Authors:  Y A Smirnov; A S Lipatov; A K Gitelman; Y Okuno; R Van Beek; A D Osterhaus; E C Claas
Journal:  Acta Virol       Date:  1999-08       Impact factor: 1.162

2.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

3.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

4.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

5.  Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.

Authors:  Shanshan Lang; Jia Xie; Xueyong Zhu; Nicholas C Wu; Richard A Lerner; Ian A Wilson
Journal:  Cell Rep       Date:  2017-09-19       Impact factor: 9.423

6.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

7.  Monoclonal anti-hemagglutinin antibodies detect irreversible antigenic alterations that coincide with the acid activation of influenza virus A/PR/834-mediated hemolysis.

Authors:  J W Yewdell; W Gerhard; T Bachi
Journal:  J Virol       Date:  1983-10       Impact factor: 5.103

8.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

9.  Defining B cell immunodominance to viruses.

Authors:  Davide Angeletti; James S Gibbs; Matthew Angel; Ivan Kosik; Heather D Hickman; Gregory M Frank; Suman R Das; Adam K Wheatley; Madhu Prabhakaran; David J Leggat; Adrian B McDermott; Jonathan W Yewdell
Journal:  Nat Immunol       Date:  2017-02-13       Impact factor: 25.606

10.  GISAID: Global initiative on sharing all influenza data - from vision to reality.

Authors:  Yuelong Shu; John McCauley
Journal:  Euro Surveill       Date:  2017-03-30
View more
  6 in total

1.  Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.

Authors:  Elaine C Chen; Pavlo Gilchuk; Seth J Zost; Naveenchandra Suryadevara; Emma S Winkler; Carly R Cabel; Elad Binshtein; Rita E Chen; Rachel E Sutton; Jessica Rodriguez; Samuel Day; Luke Myers; Andrew Trivette; Jazmean K Williams; Edgar Davidson; Shuaizhi Li; Benjamin J Doranz; Samuel K Campos; Robert H Carnahan; Curtis A Thorne; Michael S Diamond; James E Crowe
Journal:  Cell Rep       Date:  2021-08-10       Impact factor: 9.995

2.  An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.

Authors:  Naveenchandra Suryadevara; Andrea R Shiakolas; Laura A VanBlargan; Elad Binshtein; Rita E Chen; James Brett Case; Kevin J Kramer; Erica C Armstrong; Luke Myers; Andrew Trivette; Christopher Gainza; Rachel S Nargi; Christopher N Selverian; Edgar Davidson; Benjamin J Doranz; Summer M Diaz; Laura S Handal; Robert H Carnahan; Michael S Diamond; Ivelin S Georgiev; James E Crowe
Journal:  J Clin Invest       Date:  2022-06-01       Impact factor: 19.456

Review 3.  Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.

Authors:  Charles D Murin; Pavlo Gilchuk; James E Crowe; Andrew B Ward
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

4.  Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions.

Authors:  Fin J Milder; Mandy Jongeneelen; Tina Ritschel; Pascale Bouchier; Ilona J M Bisschop; Martijn de Man; Daniel Veldman; Lam Le; Baerbel Kaufmann; Mark J G Bakkers; Jarek Juraszek; Boerries Brandenburg; Johannes P M Langedijk
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

5.  Breathing and tilting: mesoscale simulations illuminate influenza glycoprotein vulnerabilities.

Authors:  Lorenzo Casalino; Christian Seitz; Julia Lederhofer; Yaroslav Tsybovsky; Ian A Wilson; Masaru Kanekiyo; Rommie E Amaro
Journal:  bioRxiv       Date:  2022-08-07

6.  Identification and analysis of B cell epitopes of hemagglutinin of H1N1 influenza virus.

Authors:  Qing Feng; Xiao-Yan Huang; Yang-Meng Feng; Li-Jun Sun; Jing-Ying Sun; Yan Li; Xin Xie; Jun Hu; Chun-Yan Guo
Journal:  Arch Microbiol       Date:  2022-09-02       Impact factor: 2.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.